1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
ReGen Biologics Inc.

ReGen Biologics Inc.

RGBOQ
ReGen Biologics Inc.US flagOther OTC
0.00
USD
- -
- -
97.00Market Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
William G. Rodkey D.V.M.
Full Time Employees
15
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
411 Hackensack Avenue Hackensack NJ United States of America 07601
IPO Date
Jun 28, 1996
Similar Companies
Sartorius Stedim Biotech S.A. (SRTOY)
Dr. Agarwal's Health Care Limited (AGARWALEYE.NS)
Kossan Rubber Industries Bhd (7153.KL)
Remedent, Inc. (REMI)
ASO International, Inc. (9340.T)
S2Medical AB (publ) (S2M.ST)
Business
ReGen Biologics Inc. (RGBOQ) designs, develops, manufactures, and markets medical devices for the repair and regeneration of soft tissue in humans, primarily targeting orthopedic applications through its proprietary collagen matrix technology with applications in orthopedics; general surgery; spine; cardiovascular; and drug delivery. The company's principal products include the Menaflex collagen meniscus implant device, utilized in surgical procedures for the reinforcement and repair of soft tissue injuries in the medial meniscus, and the SharpShooter Tissue Repair System, an instrument enabling surgeons to place needles in hard-to-reach meniscus locations. Founded in 1987 and headquartered in Hackensack, New Jersey, ReGen Biologics markets its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. In 2011, the company filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware following the FDA's rescission of 510(k) clearance for the Menaflex device, with the proceedings culminating in a court-approved Chapter 11 liquidation plan on October 14, 2011; the firm, formerly known as Aros Corp. until its name change in November 2002, also established a wholly-owned Swiss subsidiary, ReGen Biologics AG, in March 2005 to support international distribution efforts.